Evidence-based science will always trump marketing fluff. Companies should invest their resources into developing initiatives that will uncover the science. That's what truly differentiates their products. Marketing campaigns developed around evidence-based science are viewed as more credible, and the companies behind them are perceived as acting more responsibly. Pharma companies should explore tailored, one-to-one communication to introduce brands, enhance compliance, and build loyalties.
Evidence-based science will always trump marketing fluff. Companies should invest their resources into developing initiatives that will uncover the science. That's what truly differentiates their products. Marketing campaigns developed around evidence-based science are viewed as more credible, and the companies behind them are perceived as acting more responsibly. Pharma companies should explore tailored, one-to-one communication to introduce brands, enhance compliance, and build loyalties.
The pressure that pharma is experiencing from regulatory watchdog groups always has been high, but it is now at its peak. It's almost a given that any promotion perceived as disingenuous will trigger a great amount of intervention from these groups. Partly due to Sarbanes-Oxley and partly due to the increasing regulatory pressures and penalties for noncompliance, we are being required by our clients to complete their internal training programs surrounding their codes of ethics.
Some analysts and industry pundits predict the blockbuster's decline. But I have not experienced this. New blockbusters are continually being led to market. One thing we definitely know is that when pharmacogenetics and personalized medicine become mainstream—and we are closer than most people think—agencies will need an effective strategy to reach special patient populations with communication that resonates specifically with them. Portable health records, including personalized DNA analysis and reporting, will significantly advance this area of healthcare. Once this occurs, the tailored, one-to-one communication era will officially begin and the use of interactive, mobile technologies in pharma will skyrocket. With this in mind, agencies and clients must begin their exploration with these technologies now.
I'm astounded at the incredible number of companies that continue to market to physicians as if they are inhuman. Then they wonder why their marketing campaigns don't resonate. Physicians are people too. And they respond to promotional messages as any human would. To be effective, the resulting creative work must be surprising, relevant, and emotional.
Corbett Accel Healthcare Group comprises five business units. It is a member of the Omnicom Group.
Telephone: 312-664-5310
E-mail: marketmovingideas@corbettaccel.com
Web site: corbettaccel.com
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.